Global Glucocorticoid for Systemic Lupus Erythematosus
Table of Contents
2019-2024 Global Glucocorticoid for Systemic Lupus Erythematosus Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size 2014-2024
- 2.1.2 Glucocorticoid for Systemic Lupus Erythematosus Market Size CAGR by Region
- 2.2 Glucocorticoid for Systemic Lupus Erythematosus Segment by Type
- 2.2.1 Hydrocortisone
- 2.2.2 Prednison
- 2.2.3 Prednisolone
- 2.2.4 Triamcinolone Acetonide
- 2.2.5 Dexamethasone
- 2.2.6 Betamethasone
- 2.2.7 Other
- 2.3 Glucocorticoid for Systemic Lupus Erythematosus Market Size by Type
- 2.3.1 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size Growth Rate by Type (2014-2019)
- 2.4 Glucocorticoid for Systemic Lupus Erythematosus Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.4.3 Pharmacy
- 2.4.4 Other
- 2.5 Glucocorticoid for Systemic Lupus Erythematosus Market Size by Application
- 2.5.1 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size Growth Rate by Application (2014-2019)
3 Global Glucocorticoid for Systemic Lupus Erythematosus by Players
- 3.1 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size Market Share by Players
- 3.1.1 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size by Players (2017-2019)
- 3.1.2 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size Market Share by Players (2017-2019)
- 3.2 Global Glucocorticoid for Systemic Lupus Erythematosus Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Glucocorticoid for Systemic Lupus Erythematosus by Regions
- 4.1 Glucocorticoid for Systemic Lupus Erythematosus Market Size by Regions
- 4.2 Americas Glucocorticoid for Systemic Lupus Erythematosus Market Size Growth
- 4.3 APAC Glucocorticoid for Systemic Lupus Erythematosus Market Size Growth
- 4.4 Europe Glucocorticoid for Systemic Lupus Erythematosus Market Size Growth
- 4.5 Middle East & Africa Glucocorticoid for Systemic Lupus Erythematosus Market Size Growth
5 Americas
- 5.1 Americas Glucocorticoid for Systemic Lupus Erythematosus Market Size by Countries
- 5.2 Americas Glucocorticoid for Systemic Lupus Erythematosus Market Size by Type
- 5.3 Americas Glucocorticoid for Systemic Lupus Erythematosus Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Glucocorticoid for Systemic Lupus Erythematosus Market Size by Countries
- 6.2 APAC Glucocorticoid for Systemic Lupus Erythematosus Market Size by Type
- 6.3 APAC Glucocorticoid for Systemic Lupus Erythematosus Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Glucocorticoid for Systemic Lupus Erythematosus by Countries
- 7.2 Europe Glucocorticoid for Systemic Lupus Erythematosus Market Size by Type
- 7.3 Europe Glucocorticoid for Systemic Lupus Erythematosus Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Glucocorticoid for Systemic Lupus Erythematosus by Countries
- 8.2 Middle East & Africa Glucocorticoid for Systemic Lupus Erythematosus Market Size by Type
- 8.3 Middle East & Africa Glucocorticoid for Systemic Lupus Erythematosus Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Glucocorticoid for Systemic Lupus Erythematosus Market Forecast
- 10.1 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast (2019-2024)
- 10.2 Global Glucocorticoid for Systemic Lupus Erythematosus Forecast by Regions
- 10.2.1 Global Glucocorticoid for Systemic Lupus Erythematosus Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Glucocorticoid for Systemic Lupus Erythematosus Forecast by Type
- 10.8 Global Glucocorticoid for Systemic Lupus Erythematosus Forecast by Application
11 Key Players Analysis
- 11.1 Pfizer
- 11.1.1 Company Details
- 11.1.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.1.3 Pfizer Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Pfizer News
- 11.2 Sanofi
- 11.2.1 Company Details
- 11.2.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.2.3 Sanofi Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Sanofi News
- 11.3 Teva
- 11.3.1 Company Details
- 11.3.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.3.3 Teva Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Teva News
- 11.4 Akorn
- 11.4.1 Company Details
- 11.4.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.4.3 Akorn Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Akorn News
- 11.5 GSK
- 11.5.1 Company Details
- 11.5.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.5.3 GSK Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 GSK News
- 11.6 Bausch and Lomb
- 11.6.1 Company Details
- 11.6.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.6.3 Bausch and Lomb Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 Bausch and Lomb News
- 11.7 Bayer Pharmas
- 11.7.1 Company Details
- 11.7.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.7.3 Bayer Pharmas Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 Bayer Pharmas News
- 11.8 Fougera Pharms
- 11.8.1 Company Details
- 11.8.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.8.3 Fougera Pharms Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 Fougera Pharms News
- 11.9 Hikma Intl Pharms
- 11.9.1 Company Details
- 11.9.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.9.3 Hikma Intl Pharms Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.9.4 Main Business Overview
- 11.9.5 Hikma Intl Pharms News
- 11.10 Impax Labs
- 11.10.1 Company Details
- 11.10.2 Glucocorticoid for Systemic Lupus Erythematosus Product Offered
- 11.10.3 Impax Labs Glucocorticoid for Systemic Lupus Erythematosus Revenue, Gross Margin and Market Share (2017-2019)
- 11.10.4 Main Business Overview
- 11.10.5 Impax Labs News
- 11.11 Lannett
- 11.12 Merck
- 11.13 Novartis
- 11.14 Sandoz
- 11.15 TARO
- 11.16 Valeant
- 11.17 Wockhardt
- 11.18 Solvay Pharma
- 11.19 Alcon
- 11.20 Paladin Labs
- 11.21 Adcock Ingram
- 11.22 ADARE Pharmaceuticals
- 11.23 Aspen Holdings
- 11.24 Astellas Pharma
- 11.25 Endo International
- 11.26 Sun Pharmaceutical
- 11.27 Perrigo
- 11.28 Aerosol
12 Research Findings and Conclusion
According to this study, over the next five years the Glucocorticoid for Systemic Lupus Erythematosus market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Glucocorticoid for Systemic Lupus Erythematosus business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Glucocorticoid for Systemic Lupus Erythematosus market by product type, application, key companies and key regions.
This study considers the Glucocorticoid for Systemic Lupus Erythematosus value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Hydrocortisone
Prednison
Triamcinolone Acetonide
Dexamethasone
Betamethasone
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospital
Clinic
Pharmacy
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Pfizer
Sanofi
Teva
Akorn
GSK
Bausch and Lomb
Bayer Pharmas
Fougera Pharms
Hikma Intl Pharms
Impax Labs
Lannett
Merck
Novartis
Sandoz
TARO
Valeant
Wockhardt
Solvay Pharma
Alcon
Paladin Labs
Adcock Ingram
ADARE Pharmaceuticals
Aspen Holdings
Astellas Pharma
Endo International
Sun Pharmaceutical
Perrigo
Aerosol
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Glucocorticoid for Systemic Lupus Erythematosus market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Glucocorticoid for Systemic Lupus Erythematosus market by identifying its various subsegments.
Focuses on the key global Glucocorticoid for Systemic Lupus Erythematosus players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Glucocorticoid for Systemic Lupus Erythematosus with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Glucocorticoid for Systemic Lupus Erythematosus submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.